249 related articles for article (PubMed ID: 29487011)
1. Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.
Kriegsmann M; Harms A; Kazdal D; Fischer S; Stenzinger A; Leichsenring J; Penzel R; Longuespée R; Kriegsmann K; Muley T; Safi S; Warth A
Pathol Res Pract; 2018 Mar; 214(3):408-416. PubMed ID: 29487011
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
4. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
6. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer.
Li C; Hao L; Li Y; Wang S; Chen H; Zhang L; Ke B; Yin Y; Suo H; Sun B; Zhang B; Wang C
PLoS One; 2014; 9(9):e107276. PubMed ID: 25198510
[TBL] [Abstract][Full Text] [Related]
8. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.
Woo T; Okudela K; Yazawa T; Wada N; Ogawa N; Ishiwa N; Tajiri M; Rino Y; Kitamura H; Masuda M
Lung Cancer; 2009 Sep; 65(3):355-62. PubMed ID: 19162366
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
11. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
12. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
Pelosi G; Pellegrinelli A; Fabbri A; Tamborini E; Perrone F; Settanni G; Busico A; Picciani B; Testi MA; Militti L; Maisonneuve P; Valeri B; Sonzogni A; Proto C; Garassino M; De Braud F; Pastorino U
Virchows Arch; 2016 Jun; 468(6):651-62. PubMed ID: 27056568
[TBL] [Abstract][Full Text] [Related]
13. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
[TBL] [Abstract][Full Text] [Related]
14. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
15. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
Warth A
Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
[TBL] [Abstract][Full Text] [Related]
17. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
18. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
19. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
Xu L; Lei J; Wang QZ; Li J; Wu L
Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
